Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

Author： Narine L.   Hague L. K.   Walker J. H.   Vicente C.   Schilz R.   Desjardins O.   Einarson T. R.   Iskedjian M.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.21, Iss.12, 2005-12, pp. : 2007-2016

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy

By Wen A.   Weiss I.   Kelly R.  

Infection, Vol. 41, Iss. 3, 2013-06 ,pp. : 719-722

Springer Publishing Company

Access to resources Recommend Favorite

Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension—Bridge‐to‐transplant or long‐term treatment?

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis

By  

Cardiology, Vol. 120, Iss. 3, 2011-12 ,pp. : 157-165

Karger

Access to resources Recommend Favorite

Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial

By  

Respiration, Vol. 92, Iss. 6, 2016-10 ,pp. : 362-370

Karger

Access to resources Recommend Favorite

Cost‐minimization analysis of a tailored oral health intervention designed for immigrant older adults

By  

GERIATRICS & GERONTOLOGY INTERNATIONAL, Vol. 14, Iss. 2, 2014-04 ,pp. : 336-340

John Wiley & Sons Inc

Access to resources Recommend Favorite